In addition, long-term clinical outcome studies using different DPP-4 inhibitors revealed that development of adverse clinical events including heart failure and cardiovascular death did not increase with chronic DPP-4 inhibition [43,44,45]. This evidence concerns the gene DPP4 and heart failure.